Development of organotypic and organ-on-chip models of ovarian tumor to test anticancer drugs
Project objectives |
| The aim of ORGANOVA is to develop organotypic 3D models of HG-SOC, exploiting the potential of the organ-on-chip approach, as predictive in vitro models to be used in “prioritization testing” in the translation between in vitro and in vivo. The 3D models will first be validated for the response to drugs in use in current clinical practice, and will subsequently be employed for the testing of new molecules. This will allow an effective selection of the “lead” molecules to be sent to preclinical in vivo testing. |
Start and end date |
| April 2021 – November 2023 |
Project Manager |
| Alberto Rainer |
Coordinating institution of the project |
| National Research Center (CNR) |
Other Institutions involved |
None |
Funding source(s). |
| Regional Funds POR-FESR Lazio 2014/2020, "Research Groups 2020" |